(Q33383208)

26 July 2017

title

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

1 reference

9

David Gandara

1 reference

26 July 2017

Leonid L Yavorkovsky

6

1 reference

ORCID Public Data File 2021

author name string

Gigi Chen

1

1 reference

26 July 2017

Minh Huynh

2

1 reference

26 July 2017

Lou Fehrenbacher

3

1 reference

26 July 2017

Howard West

4

1 reference

26 July 2017

Primo N Lara

5

1 reference

26 July 2017

Michael Russin

7

1 reference

26 July 2017

Desiree Goldstein

8

1 reference

26 July 2017

Derick Lau

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 February 2009

1 reference

Journal of Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

27

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

1401-1404

1 reference

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Chemotherapy for brain metastases in small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Population-based maximum tolerated dose of irinotecan and carboplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Prediction of creatinine clearance from serum creatinine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2668551

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19204194

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19204194

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Measuring response in solid tumors: unidimensional versus bidimensional measurement

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19204194

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.20.2127

1 reference

26 July 2017

1 reference

26 July 2017

1 reference